Moloxin (Moxifloxacin)

Moxifloxacin, the active ingredient in Moloxin, is a fluoroquinolone presented as an oral tablet for oral use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and skin and soft‑tissue infections in adults. It is indicated for adult patients and is marketed in the European Union.

GNH USA supplies Moloxin as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide and supporting procurement teams with regulatory documentation, quality assurance, and reliable logistics across multiple jurisdictions.

Moxifloxacin is a fluoroquinolone antibacterial that targets bacterial DNA replication, making it effective for several respiratory and skin infections.

- Community‑acquired pneumonia: improves clinical cure rates and reduces bacterial load in adult patients. - Acute bacterial sinusitis: alleviates sinus inflammation and eradicates causative pathogens. - Acute bacterial exacerbation of chronic bronchitis: shortens symptom duration and prevents further lung damage. - Skin and soft‑tissue infections: resolves bacterial cellulitis and related dermal infections.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, occasionally watery. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Abdominal pain: cramping or discomfort. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: anaphylaxis, angioedema. - Clostridioides difficile infection: severe colitis. - Hepatic enzyme elevation: potential liver injury. - Photosensitivity: heightened skin reaction to sunlight.

Before prescribing Moloxin, clinicians should consider several safety measures.

- Assess renal function: adjust use in severe renal impairment. - Evaluate hypersensitivity: avoid in patients with known fluoroquinolone allergy. - Use cautiously in the elderly: increased risk of tendon injury. - Monitor cardiac status: may prolong QT interval, especially with other QT‑prolonging agents. - Avoid concomitant NSAIDs in patients at risk of seizures: may lower seizure threshold. - Store at room temperature: keep in the original pack, protect from moisture and light.

Moxifloxacin can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Systemic corticosteroids: increased risk of tendon rupture. - Other QT‑prolonging drugs (e.g., quinidine, macrolides): heightened arrhythmia risk. - Antacids containing aluminum or magnesium: reduce moxifloxacin absorption. - Warfarin: may enhance anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., fluvoxamine): may raise moxifloxacin plasma levels. - Diabetic agents (insulin, sulfonylureas): possible alterations in glucose control. - Theophylline: increased risk of theophylline toxicity.